Written by Steven Hansen
The U.S. new cases 7-day rolling average are 2.0 % HIGHER than the 7-day rolling average one week ago. U.S. hospitalizations due to COVID-19 are now 13.4 % LOWER than the rolling average one week ago. U.S. deaths due to coronavirus are now 13.9 % LOWER than the rolling average one week ago. Today’s posts include:
- U.S. Coronavirus New Cases are 77,291
- U.S. Coronavirus hospitalizations are at 52,669
- U.S. Coronavirus deaths are at 2,417
- U.S. Coronavirus immunizations have been administered to 20.4 % of the population
- The 7-day rolling average rate of growth of the pandemic shows new cases worsened, hospitalizations worsened, and deaths worsened [note: this is a sign of trend reversal – could the new variants be impacting COVID case growth?>
As of the time of publishing this post, the Johnson & Johnson vaccine has not yet received its expected emergency use authorization.- Update at 19:07 – An FDA advisory committee voted unanimously Friday to recommend the Johnson & Johnson COVID-19 vaccine (Ad26.COV2.S) for use in adults 18 and older
- Reassessing COVID-19 Vaccine Deployment in Anticipation of a US B.1.1.7 Surge: Stay the Course or Pivot?
- FDA Allows More Flexible Storage, Transportation Conditions for Pfizer-BioNTech COVID-19 Vaccine
- Scientists Discover ‘All-Natural’ COVID Treatment That Can Prevent ‘Cytokine Storm’ In Severe Patients
- The Simple Habit of Flossing Reduces Your Risk Of COVID-19 Complications
- Wearing glasses may protect against COVID-19, study finds
- US to Buy at Least 100K Doses of Lilly’s COVID-19 Antibody Therapy
- Assessing mandatory stayâ€atâ€home and business closure effects on the spread of COVIDâ€19
- Vaccination ‘passports’ may open society, but inequity looms
The recent worsening of the trendlines for new cases is behind us which was attributed to going back to college/university, cooler weather causing more indoor activities, mutation of the virus, fatigue from wearing masks / social distancing, holiday activities, and some loosening of regulations designed to slow the coronavirus spread.
My continuing advice is to continue to wash your hands (especially after using the toilet as COVID first sheds in your stool), putting down the toilet seat (as flushing the toilet releases a plume), wear masks, avoid crowds, and maintain social distancing. No handwashing, mask, or social distancing will guarantee you do not get infected – but it sure as hell lowers the risk in all situations – and the evidence to-date shows a lower severity of COVID-19. In addition, certain activities are believed to carry higher risk – like being inside in air conditioning and removing your mask (such as restaurants, around your children/grandchildren, bars, and gyms). It is all about viral load – and outdoor activities are generally safe if you can maintain social distance. Finally, studies show eating right (making sure you are supporting your immune system) and adequate sleep increase your ability to fight off COVID.
include($_SERVER[‘DOCUMENT_ROOT’].’/pages/coronavirus1.htm’); ?>
Hospitalizations Are The Only Accurate Gauge As Reporting Is Not Affected By Holidays
The 4 day Thanksgiving holiday period put the first wobble in the trends. Over weekends and holidays, the number of new cases and deaths decline. Over weekends, this is not a problem for week-over-week rolling averages as weekends are compared against the previous weekend. But when a holiday falls within a working week, a non-working day is compared to a working day which causes havok in the trends.
However, hospitalizations historically appear to be little affected by weekends or holidays – the daily counts do not vary significantly from day-to-day.
The hospitalization growth rate trend is improving.
For the Thanksgiving and the end of the year holiday period – roughly, it seems each appears to have added around 5 % to the rate of growth of new cases, hospitalizations, and deaths.
Historically, hospitalization growth follows new case growth by one to two weeks.
As an analyst, I use the rate of growth to determine the trend. But, the size of the pandemic is growing in terms of real numbers – and if the rate of growth does not become negative – the pandemic will overwhelm all resources.
The graph below shows the rate of growth relative to the growth a week earlier updated through today [note that negative numbers mean the rolling averages are LOWER than the rolling averages one week ago]. As one can see, the rate of growth for new cases peaked in early December 2020 for Thanksgiving, and early January 2021 for end of year holidays – and the rate of growth is now contracting.
In the scheme of things, new cases decline first, followed by hospitalizations, and then deaths.
It is up to each of our readers to protect themselves and others by washing hands, wearing a mask, avoiding crowds, and maintaining social distancing.
Will The New Variants Cause The Next Spike?
Maybe and maybe not. It all depends on vaccinations:
- the more people that are vaccinated reduces the pool of people that can be infected. Today we have removed over 20 % of the population from being infected which theoretically should reduce the infection rate by 20 % [it is unstudied whether the vaccines prevent a vaccinated person from being a carrier of the virus even though showing no signs]. If the vaccines are shown to stop transmission, then in theory it would reduce the infection rate by double the percent vaccinated [in this case you prevent your own infection and do not pass it along to another].
- it is also unknown what the effective rate of the current vaccines is against mutations that seem to appear almost daily. As an example, if the effective rate drops to 60%, it means the 20 % reduction in the infection rate discussed above is almost cut in half. The South African and Brazilian variant is somewhat immune to the current vaccines.
- The pandemic should be over immediately if everyone could be vaccinated today. The problem is that every day brings a new mutation (which would not appear if the pandemic was stopped). The longer the immunization process takes – the more ineffective the vaccine will become.
- It is not clear whether the vaccine prevents those vaccinated from spreading the virus. It seems to be well documented that it normally stops the virus from taking hold and when it does not – the infection is mild.
Coronavirus News You May Have Missed
To address the possible surge in COVID-19 cases in the US due to the B.1.1.7 variant, officials need to consider now a strategic shift in deployment of vaccines. It will likely take a minimum of 3 weeks to initiate any change in the vaccine program, and the B.1.1.7 variant is well on its way to becoming the dominant strain in the US. 10 Public health officials and agencies hold the responsibility for strategic vaccine deployment for authorized vaccines. Now is the time to make critical decisions with imperfect data. However, compared to when the mRNA vaccines were authorized, we have more complete data regarding the B.1.17 variants. We know how the B.1.1.7 variant evolved and led to surges in other countries, and we know that the early evolution of B.1.1.7 in the US mirrors that of Europe. An emergency joint session of VRBPAC and the ACIP should be conducted to review all existing data and determine how to optimize the current supply. Consideration of vaccinating the maximum number of older adults possible, deferring second doses, and using a reduced dosage approach for the Moderna vaccine could possibly save thousands of lives in the upcoming months. Preparing for a potential B.1.1.7 surge will require public health agencies to act urgently based on the best science and with the intent to save as many lives as possible from COVID-19.
FDA Allows More Flexible Storage, Transportation Conditions for Pfizer-BioNTech COVID-19 Vaccine – FDA
Today, the U.S. Food and Drug Administration announced that it is allowing undiluted frozen vials of the Pfizer-BioNTech COVID-19 Vaccine to be transported and stored at conventional temperatures commonly found in pharmaceutical freezers for a period of up to two weeks. This reflects an alternative to the preferred storage of the undiluted vials in an ultra-low temperature freezer between -80C to -60C (-112F to -76F). The change is being reflected in updates to the Fact Sheet for Healthcare Providers Administering Vaccine (Vaccination Providers).
“Pfizer submitted data to the FDA to support this alternative temperature for transportation and storage. This alternative temperature for transportation and storage of the undiluted vials is significant and allows the vials to be transported and stored under more flexible conditions. The alternative temperature for transportation and storage will help ease the burden of procuring ultra-low cold storage equipment for vaccination sites and should help to get vaccine to more sites,” said Peter Marks, M.D., Ph.D., director of the FDA’s Center for Biologics Evaluation and Research.
Assessing mandatory stayâ€atâ€home and business closure effects on the spread of COVIDâ€19 – ESCI
The most restrictive nonpharmaceutical interventions (NPIs) for controlling the spread of COVIDâ€19 are mandatory stayâ€atâ€home and business closures. Given the consequences of these policies, it is important to assess their effects. We evaluate the effects on epidemic case growth of more restrictive NPIs (mrNPIs), above and beyond those of lessâ€restrictive NPIs (lrNPIs).
Methods
We first estimate COVIDâ€19 case growth in relation to any NPI implementation in subnational regions of 10 countries: England, France, Germany, Iran, Italy, Netherlands, Spain, South Korea, Sweden and the United States. Using firstâ€difference models with fixed effects, we isolate the effects of mrNPIs by subtracting the combined effects of lrNPIs and epidemic dynamics from all NPIs. We use case growth in Sweden and South Korea, 2 countries that did not implement mandatory stayâ€atâ€home and business closures, as comparison countries for the other 8 countries (16 total comparisons).
Results
Implementing any NPIs was associated with significant reductions in case growth in 9 out of 10 study countries, including South Korea and Sweden that implemented only lrNPIs (Spain had a nonsignificant effect). After subtracting the epidemic and lrNPI effects, we find no clear, significant beneficial effect of mrNPIs on case growth in any country. In France, for example, the effect of mrNPIs was +7% (95% CI: 5%â€19%) when compared with Sweden and + 13% (12%â€38%) when compared with South Korea (positive means proâ€contagion). The 95% confidence intervals excluded 30% declines in all 16 comparisons and 15% declines in 11/16 comparisons.
Conclusions
While small benefits cannot be excluded, we do not find significant benefits on case growth of more restrictive NPIs. Similar reductions in case growth may be achievable with lessâ€restrictive interventions.
Scientists Discover ‘All-Natural’ COVID Treatment That Can Prevent ‘Cytokine Storm’ In Severe Patients – ZeroHedge
A team of scientists from Israel and Iceland has published a new report showing that an extraction of spirulina algae has the potential to reduce the severity of COVID-19 in advanced cases.
The research, first published in a peer-reviewed journal called Marine Biotechnology, found that an extract of photosynthetically manipulated Spirulina is 70% effective in inhibiting the release of the cytokine TNF-a, a small signaling protein used by the immune system.
According to the Jerusalem Post, the research was conducted in a MIGAL laboratory in northern Israel with algae grown and cultivated in Iceland by the Israeli company VAXA. VAXA received funding from the European Union to explore and develop “natural” treatments for coronavirus.
In a small percentage of patients, infection with the coronavirus causes the immune system to release an excessive number of TNF-a cytokines, resulting in what is known as a cytokine storm. The storm causes acute respiratory distress syndrome and damage to other organs, the leading cause of death in COVID-19 patients.
“If you control or are able to mitigate the excessive release of TNF-a, you can eventually reduce mortality,” said Asaf Tzachor, a researcher from the IDC Herzliya School of Sustainability and the lead author of the study.
Vaccination ‘passports’ may open society, but inequity looms – AP
… Governments say getting vaccinated and having proper documentation will smooth the way to travel, entertainment and other social gatherings in a post-pandemic world.
But it also raises the prospect of further dividing the world along the lines of wealth and vaccine access, creating ethical and logistical issues that have alarmed decision-makers around the world.
Other governments are watching Israel churn through the world’s fastest vaccination program and grapple with the ethics of using the shots as diplomatic currency and power.
Inside Israel, green passports or badges obtained through an app is the coin of the realm. The country recently reached agreements with Greece and Cyprus to recognize each other’s green badges, and more such tourism-boosting accords are expected.
Anyone unwilling or unable to get the jabs that confer immunity will be “left behind,” said Health Minister Yuli Edelstein.
… Most countries don’t have enough vaccine, highlighting the fraught ethical landscape of who can get it and how to lift the burden of COVID-19.
“The core human rights principle is equity and non-discrimination,” said Lawrence Gostin, a Georgetown University professor and director of the World Health Organization Collaborating Center on National and Global Health Law.
“There’s a huge moral crisis in equity globally because, in high-income countries like Israel or the United States or the EU countries, we’re likely to get to herd immunity by the end of this year,” he said. “But for many low-income countries, most people won’t be vaccinated for many years. Do we really want to give priority to people who already have so many privileges?”
It’s a question dogging the international community as wealthier countries begin to gain traction against the coronavirus and some of its variants.
US to Buy at Least 100K Doses of Lilly’s COVID-19 Antibody Therapy – Newsmax
Drugmaker Eli Lilly and Co said on Friday the U.S. government has agreed to buy at least 100,000 doses of its newly authorized COVID-19 dual antibody cocktail for $210 million, with doses to be delivered through March-end.
The U.S. government will have the option to purchase up to an additional 1.1 million doses through Nov. 25, the company said.
The therapy contains two antibodies, bamlanivimab and etesevimab, and had got U.S. emergency use authorization earlier this month for the treatment of mild to moderate COVID-19 in patients who are at high risk of progressing to severe disease or hospitalization.
The United States had already agreed to buy 1.45 million doses of bamlanivimab alone, Lilly said, adding that 1 million of doses have already been delivered and 450,000 additional doses will be delivered by March-end.
The Simple Habit of Flossing Reduces Your Risk Of COVID-19 Complications, Says New Study – Good News Network
The Journal of Clinical Periodontology found that people with COVID-19 and gum disease had a 900% greater chance of dying from the virus, while also being 350% more likely to be hospitalized.
While the two phenomena seem completely unrelated, the correlation is simply the result of chronic inflammation, spurred on by diseased gums, exacerbating the inflammatory response generated by the SARS-CoV-2.
This knock on effect is quite common in pathology, with some inflammatory responses like interleukin (IL) and tumor-necrosis-factor (TNF) being correspondingly found in nearly every disease known to man. IL-6 is a principal factor in COVID-19 mortality for example.
The cause is simply the function that different immune agents have on our body. One of the leading inducers of death in COVID-19-afflicted patients is the much-discussed “cytokine storm” referring to inflammatory cytokines, a type of immune cell, targeting our own tissues with such fury that they cannot survive.
[editor’s note: this goes hand-in-hand with Could mouthwashes help reduce coronavirus transmission?]
It’s called ‘nerd immunity’: Wearing glasses may protect against COVID-19, study finds – Penn Live
… when it comes to protection against COVID-19, a new study has found that wearing glasses may be worth the frustration.
According to a report by WKYC 3, multiple studies have shown that of the people who contract COVID-19, those who wear glasses at least eight hours a day make up a lesser percentage of that group than those who don’t wear glasses.
The report cited Professor Yaneer Bar-Yam of The New England Complex Systems Institute who said: “If something lands in your eye, it can go through a duct that goes down into your nose and that’s how it might infect you.”
WKYC 3 cited a study published this month in India, which looked at 304 COVID-19 patients. The author says “about 40% of India’s adult population wears glasses, but only 19% of the people infected with coronavirus wore glasses.” The conclusion reached by the researchers was that “the risk of COVID-19 was about 2 to 3 times less in the spectacles wearing population than the population not wearing them.”
WKYC 3 again cited Professor Bar-Yam, who said: “Probably one of the main pieces is that the air particles will get deposited on your glasses as well as you might not touch your eyes a little bit, but it’s really important to know that this is in addition to wearing a mask.”
Bar-Yam added that these results “mirror a previous study he saw from China.”
‘A Very Concerning Shift’: CDC Head Warns Of Recent Uptick In COVID-19 Cases – NPR
The head of the Centers for Disease Control and Prevention warned Friday of an uptick in the country’s confirmed COVID-19 cases, saying recent progress may be “stalling” as highly infectious new variants become more predominant.
Dr. Rochelle Walensky said at a White House briefing that after weeks of declining cases and hospitalizations, the 7-day average in confirmed cases has ticked up in the past three days in what the CDC considers a “very concerning shift in trajectory.” The most recent 7-day average of deaths is at about 2,000 per day, she said, which is slightly higher than that of the week before.
“Things are tenuous. Now is not the time to relax restrictions,” Walensky said. “Although we have been experiencing large declines in cases and hospital admissions over the past six weeks, these declines follow the highest peak we have experienced in the pandemic.”
In other words, she said, the decline in cases could taper off at a level that is still dangerously high.
[editor’s note: also read U.S. health officials caution governors against easing restrictions, warning that a recent plunge in virus cases ‘may be stalling and The virus is on course to return, but there’s still time to stop it . and Declines in US Covid-19 cases and hospitalizations are stalling, CDC director warns and US “may now be seeing the beginning effects of these variants,” CDC head warns]
The following are foreign headlines with hyperlinks to the posts
Brazil Death Toll: The country’s death toll has surpassed 250,000. It is the world’s second-highest after the U.S., and the virus continues to run rampant in the country.
Israel approves bill allowing names of unvaccinated to be shared with authorities
Left out? Israeli vaccine refuseniks fear exclusion
Ivory Coast has become the second country in the world to receive a shipment of COVID-19 vaccines from the global COVAX initiative. The first shipment was sent to Ghana on Wednesday.
Queen Elizabeth II encourages COVID-19 vaccinations
The city of Nice, France, is closing its iconic Promenade des Anglais beachside walkway this weekend to help stem COVID transmission.
Israeli vaccination campaign leads to plunge in severe COVID-19 cases
France announces stricter coronavirus checks at German border
South Korea, Hong Kong administer first coronavirus vaccines
EU Regulator Plans to Fast Track Variant-Modified COVID Vaccines
Nigeria expects to receive 4 million vaccine doses next week, WHO official says
Japan to end state of emergency due to Covid-19 for 6 prefectures this month
India has supplied over 36 million doses of COVID-19 vaccines abroad so far
The following additional national and state headlines with hyperlinks to the posts
COVID cases in nursing homes drop 89%
U.S. Hospitals: The number of people hospitalized with COVID-19 in the U.S. has plummeted by 80,000 in six weeks, and 17% of the nation’s adult population has gotten at least one dose of vaccine.
Best Buy expected to close more stores in 2021
In partnership with Boston Children’s Hospital and Castlight Health, the CDC launched a new online tool to help connect Americans with vaccine appointments.
High-intensity fitness classes at the gym are acting as mini super-spreader events.
New York City officials aren’t convinced that the new variant spreading across the city poses serious concern; one called media reports “pathogen porn.”
States will soon know what to expect about vaccine shipments months in advance.
As many insurance companies’ cost-sharing waivers for COVID-19 are fizzling out, the average patient over 65 is hit with $1,000 in bills after being discharged.
Julia Roberts virtually presented Anthony Fauci, MD, with the amfAR Foundation for AIDS Research’s Award of Courage.
CDC: Nursing Home Cases Suggest COVID Reinfection
One dose of Pfizer vaccine offers significant protection for those who have had COVID-19: studies
Navy reports 2 ships in Middle East facing coronavirus outbreaks
Pfizer-BioNTech Testing Booster of COVID Vaccine in New Trial
Biden’s COVID Bill Rebuilds the Welfare State that Bill Clinton Dismantled
Unlike Trump’s COVID bills, Biden’s Plan Largely Spends Money On The Virus
Federal Judge Rules CDC Order Halting Evictions During Pandemic is Unconstitutional
Richard A. Carranza will resign as chancellor of New York City’s public school system, the nation’s largest, in March, city officials announced Friday. The abrupt move comes after disagreements between Mayor Bill de Blasio and Mr. Carranza over school desegregation policy reached a breaking point in recent weeks.
White House launches new federal Covid-19 vaccination sites in North Carolina and Illinois
FCC approves $50-a-month internet subsidies for pandemic-stricken households
Fully vaccinated people can gather individually with minimal risk, Fauci says
Today’s Posts On Econintersect Showing Impact Of The Pandemic With Hyperlinks
19 February 2021 ECRI’s WLI Growth Rate Modestly Improves
Final February 2021 Michigan Consumer Sentiment Up From Preliminary
February 2021 Chicago Purchasing Managers Barometer Declines
January 2021 Real Income Grew Due To Stimulus
Rail Week Ending 13 February 2021 – A Real Bad Week For Rail
Why Black And Hispanic Small-Business Owners Have Been So Badly Hit In The Pandemic Recession
US States Hit Hardest By Covid-19
Warning to Readers
The amount of politically biased articles on the internet continues to increase. And studies and opinions of the experts continue to contradict other studies and expert opinions. Honestly, it is difficult to believe anything anymore.
I assemble this coronavirus update daily – sifting through the posts on the internet. I try to avoid politically slanted posts (mostly from CNN, New York Times, and the Washington Post) and can usually find unslanted posts on that subject from other sources on the internet. I wait to publish posts on subjects that I cannot validate across several sources. But after all this extra work, I do not know if I have conveyed the REAL facts. It is my job to provide information so that you have the facts necessary – and then it is up to readers to draw conclusions.
Analyst Opinion of Coronavirus Data
There are several takeaways that need to be understood when viewing coronavirus statistical data:
- The global counts are suspect for a variety of reasons including political. Even the U.S. count has issues as it is possible that as much as half the population has had coronavirus and was asymptomatic. It would be a far better metric using a random sampling of the population weekly. In short, we do not understand the size of the error in the tracking numbers.
- Just because some of the methodology used in aggregating the data in the U.S. is flawed – as long as the flaw is uniformly applied – you establish a baseline. This is why it is dangerous to compare two countries as they likely use different methodologies to determine who has (and who died) from coronavirus.
- COVID-19 and the flu are different but can have similar symptoms. For sure, COVID-19 so far is much more deadly than the flu. [click here to compare symptoms]
- From an industrial engineering point of view, one can argue that it is best to flatten the curve only to the point that the health care system is barely able to cope. This solution only works if-and-only-if one can catch this coronavirus once and develops immunity. In the case of COVID-19, herd immunity may need to be in the 80% to 85% range. WHO warns that few have developed antibodies to COVID-19 when recovering from COVID-19. Herd immunity does not look like an option without immunization although there is now a discussion of whether T-Cells play a part in immunity [which means one might have immunity without antibodies]
- Older population countries will have a significantly higher death rate as there is relatively few hospitalizations and deaths in younger age groups..
- There are at least 8 strains of the coronavirus. New York may have a deadlier strain imported from Europe, compared to less deadly viruses elsewhere in the United States.
- Each publication uses different cutoff times for its coronavirus statistics. Our data uses 11:00 am London time. Also, there is an unexplained variation in the total numbers both globally and in the U.S.
What we do or do not know about the coronavirus [actually there is little scientifically proven information]. Most of our knowledge is anecdotal, from studies with limited subjects, or from studies without peer review.
- How many people have been infected as many do not show symptoms?
- Masks do work. Unfortunately, early in the pandemic, many health experts – in the U.S. and around the world – decided that the public could not be trusted to hear the truth about masks. Instead, the experts spread a misleading message, discouraging the use of masks.
- Current thinking is that we develop 5 months of immunity from further COVID infection.
- The Moderna and Pfizer vaccines have an effectiveness rate of about 95 percent after two doses. That is on par with the vaccines for chickenpox and measles. The 95 percent number understates the effectivenessas it counts anyone who came down with a mild case of Covid-19 as a failure. But turning Covid into a typical flu – as the vaccines evidently did for most of the remaining 5 percent – is actually a success. Of the 32,000 people who received the Moderna or Pfizer vaccine in a research trial, only one contracted a severe Covid case.
- To what degree do people who never develop symptoms contribute to transmission? Research early in the pandemic suggested that the rate of asymptomatic infections could be as high as 81%. But a meta-analysis, which included 13 studies involving 21,708 people, calculated the rate of asymptomatic presentation to be 17%.
- The accuracy of rapid testing is questioned – and the more accurate test results are not being given in a timely manner.
- Can children widely spread coronavirus? [current thinking is that they are a minor source of the pandemic spread]
- Why have some places avoided big coronavirus outbreaks – and others hit hard?
- Air conditioning contributes to the pandemic spread.
- It appears that there is increased risk of infection and mortality for those living in larger occupancy households.
- Male patients have almost three times the odds of requiring intensive treatment unit (ITU) admission compared to females.
- Outdoor activities seem to be a lower risk than indoor activities.
- Will other medical treatments for Covid-19 ease symptoms and reduce deaths? So far only remdesivir, Bamlanivimab,
and Regeneron) are approved for treatment. What drugs work? Arthritis drugs tocilizumab and sarilumab could cut relative risk of death of those in intensive care by 24%
- A current scientific understanding of the way the coronavirus works can be found [here].
There is now a vaccine available – the questions remain:
- how effective it will be in the general population,
- will there be any permanent side effects that will appear months from now,
- how long immunity will last [we can currently say we do not know if it will last more than 4 months],
- there is no evidence the vaccine will block transmission
Heavy breakouts of coronavirus have hit farmworkers. Farmworkers are essential to the food supply. They cannot shelter at home. Consider:
- they have high rates of respiratory disease [occupational hazard]
- they travel on crowded buses chartered by their employers
- few have health insurance
- they cannot social distance and live two to four to a room – and they eat together
- some reports say half are undocumented
- they are low paid and cannot afford not to work – so they will go to work sick
- they do not have access to sanitation when working
- a coronavirus outbreak among farmworkers can potentially shutter entire farm
The bottom line is that COVID-19 so far has been shown to be much more deadly than the data on the flu. Using CDC data, the flu has a mortality rate between 0.06 % and 0.11 % Vs. the coronavirus which to date has a mortality rate of 4 % [the 4% is the average of overall statistics – however in the last few months it has been hovering around 1.0%] – which makes it between 10 and 80 times more deadly. The reason for ranges:
Because influenza surveillance does not capture all cases of flu that occur in the U.S., CDC provides these estimated ranges to better reflect the larger burden of influenza.
There will be a commission set up after this pandemic ends to find fault [it is easy to find fault when a once-in-a-lifetime event occurs] and to produce recommendations for the next time a pandemic happens. Those that hate President Trump will conclude the virus is his fault.
Resources:
- Get the latest public health information from CDC: https://www.coronavirus.gov .
- Get the latest research from NIH: https://www.nih.gov/coronavirus.
- Find NCBI SARS-CoV-2 literature, sequence, and clinical content: https://www.ncbi.nlm.nih.gov/sars-cov-2/.
- List of studies: https://icite.od.nih.gov/covid19/search/#search:searchId=5ee124ed70bb967c49672dad
include(“/home/aleta/public_html/files/ad_openx.htm”); ?>